Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy

被引：0
|
作者：
Pierre Blanchard
Laurent Quero
Vincent Pacault
Marie-Helene Schlageter
Valerie Baruch-Hennequin
Christophe Hennequin
机构：
[1] Hôpital Saint Louis,Radiation Oncology Department
[2] AP-HP,Radiation Oncology Department
[3] Institut Gustave Roussy,Unité de Biologie Cellulaire
[4] Hôpital Saint Louis,Radiation Oncology Department
[5] AP-HP,undefined
[6] Hôpital Saint Louis,undefined
来源：
BMC Cancer | / 12卷
关键词：
Esophageal cancer; Radiotherapy; Chemotherapy; p53; Ras;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy
    Blanchard, Pierre
    Quero, Laurent
    Pacault, Vincent
    Schlageter, Marie-Helene
    Baruch-Hennequin, Valerie
    Hennequin, Christophe
    BMC CANCER, 2012, 12
  • [2] Circulating anti-p53 antibodies in esophageal cancer patients
    Kozlowski, M
    Kovalchuk, O
    Niklinski, J
    Chyczewski, L
    Staroslawska, E
    Ciechanski, A
    Dabrowski, A
    Niklinska, W
    Dziegielewski, P
    Lapuc, G
    Wallner, G
    Laudanski, J
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2001, 39 : 173 - 174
  • [3] Prognostic implications of circulating anti-p53 antibodies in lung cancer - a review
    Kumar, S.
    Mohan, A.
    Guleria, R.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (03) : 248 - 254
  • [4] Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma
    Saffroy, R
    Lelong, JC
    Azoulay, D
    Salvucci, M
    Reynes, M
    Bismuth, H
    Debuire, B
    Lemoine, A
    BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) : 604 - 610
  • [5] Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma
    R Saffroy
    J-C Lelong
    D Azoulay
    M Salvucci
    M Reynes
    H Bismuth
    B Debuire
    A Lemoine
    British Journal of Cancer, 1999, 79 : 604 - 610
  • [6] Prognostic significance of serum anti-p53 antibodies in patients with hepatocellular carcinoma.
    Shiota, G
    Kishimoto, Y
    Harada, K
    Hori, K
    Okubo, M
    Ishida, M
    Okano, J
    Suyama, A
    Suou, T
    Kawasaki, H
    HEPATOLOGY, 1996, 24 (04) : 1813 - 1813
  • [7] Serum anti-p53 antibodies in patients with lung cancer
    Mack, U
    Ukena, D
    Montenarh, M
    Sybrecht, GW
    ONCOLOGY REPORTS, 2000, 7 (03) : 669 - 674
  • [8] Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors
    vonBrevern, MC
    Hollstein, MC
    Cawley, HM
    DeBenedetti, VMG
    Bennett, WP
    Liang, L
    He, AG
    Zhu, SM
    Tursz, T
    Janin, N
    Trivers, GE
    CANCER RESEARCH, 1996, 56 (21) : 4917 - 4921
  • [9] Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking
    Li, YL
    Brandt-Rauf, PW
    Carney, WP
    Tenney, DY
    Ford, JG
    BIOMARKERS, 1999, 4 (05) : 381 - 390
  • [10] Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma
    Tangkijvanich, P
    Janchai, A
    Charuruks, N
    Kullavanijaya, P
    Theamboonlers, A
    Hirsch, P
    Poovorawan, Y
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2000, 18 (04): : 237 - 243
12345